Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease
Open Access
- 11 May 2021
- journal article
- review article
- Published by Springer Nature in Current Diabetes Reports
- Vol. 21 (7) , 1-6
Abstract
Purpose of Review: Diabetic kidney disease (DKD), a leading cause of end-stage kidney disease, is the result of metabolic network alterations in the kidney. Therefore, metabolomics is an effective tool for understanding its pathophysiology, finding key biomarkers, and developing a new treatment strategy. In this review, we summarize the application of metabolomics to DKD research. Recent Findings: Alterations in renal energy metabolism including the accumulation of tricarboxylic acid cycle and glucose metabolites are observed in the early stage of DKD, and they finally lead to mitochondrial dysfunction in advanced DKD. Mitochondrial fission-fusion imbalance and dysregulated organelle crosstalk might contribute to this process. Moreover, metabolomics has identified several uremic toxins including phenyl sulfate and tryptophan derivatives as promising biomarkers that mediate DKD progression. Summary: Recent advances in metabolomics have clarified the role of dysregulated energy metabolism and uremic toxins in DKD pathophysiology. Integration of multi-omics data will provide additional information for identifying critical drivers of DKD.Keywords
This publication has 36 references indexed in Scilit:
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetesJournal of Diabetes and its Complications, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- An overview of renal metabolomicsKidney International, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent KillerAmerican Journal of Nephrology, 2016
- Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis developmentNature Medicine, 2014
- Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney DiseaseJournal of the American Society of Nephrology, 2013